Greiner Bio-One can look back on a successful 2017 financial year


Greiner Bio-One had a successful business year in 2017, further reinforcing its market position thanks to strong growth, new sites and innovative product solutions. The takeover of its longstanding,exclusive distribution partners VACUETTE España and VACUETTE Portugal in March 2017 has enabled greater proximity to customers and targeted market cultivation.

As a result of that takeover, Greiner Bio-One now has its own subsidiaries on two further key markets in Europe. In addition, the headquarters in Kremsmünster were expanded and an investment was made in a warehouse facility at the site in Hungary.

“We are investing sustainably in our locations and in innovative product solutions in order to meet the needs of our customers”, says Rainer Perneker, CEO of the Greiner Bio-One International GmbH.

Expanded range and product developments
In July 2017, Greiner Bio-One acquired 90% of shares in Vigmed Holding AB, a listed technology and trade company based in Helsingborg, Sweden. That has enabled I.V. catheters with a safety mechanism to be added to the Preanalytics safety products range. Another innovation on the market is the MiniCollect® Complete tube – a version in which the MiniCollect® standard tube is irreversibly assembled in a carrier tube. That enhancement enables easier, more efficient and more hygienic handling, since both blood collection and subsequent analyses can be performed using the same sample vessel.

news - 13470-Rainer_Perneker_Greiner_Bio-One.jpg

In addition, Greiner eHealth Technologies (GeT) achieved a significant success in 2017 with implementation of its digital, fully process-optimized system solution for preanalytical and postanalytical processes as a pilot project at the Styria General Hospital (Austria). By combining VACUETTE® barcode tubes with a software solution, GeT plays an important part in optimising preanalytical and postanalytical processes and ensuring enhanced data privacy, patient safety and quality.

Thanks to the new and innovative NIMBUS® and STARlet CXTM platforms of the BioScience division, all manual pipetting steps of the PapilloCheck® HPV test can be automated and qualitative detection of HPV (human papillomavirus) is faster and more efficient. Together with technology provided by cooperation partner Nano3D Biosciences in Houston (USA), the CELLSTAR® cell culture vessels with a cell-repellent service achieve particularly good results in the cultivation of 3D cell structures.

Greiner Bio-One has big plans for 2018
Greiner Bio-One has set itself ambitious goals for 2018. One focus will be on expanding its
market position in Asia and North America. In addition, it plans to establish new distribution subsidiaries outside of Europe. The further expansion of services and product training courses for our customers will also play a key role this year. Production capacity will be increased at several sites worldwide. In Frickenhausen (Germany), construction of a new high-bay warehouse is set to be completed and work is scheduled to begin on the second phase of extending the office and production areas.

Greiner Bio-One International GmbH
Greiner Bio-One specialises in the development, production and distribution of high-quality plastic laboratory products. The company is a technology partner for hospitals, laboratories, universities, research institutes, and the diagnostic, pharmaceutical and biotechnology industries. Greiner Bio-One is split into three divisions – Preanalytics, BioScience and Sterilisation. As an Original Equipment Manufacturer (OEM), Greiner Bio-One provides individual solutions in the area of custom-made design developments and production processes for the life sciences and medical sectors.

In 2017, Greiner Bio-One International GmbH generated a turnover of 473 million euros and had over 2,200 employees,26 subsidiaries and numerous distribution partners in over 100 countries. Greiner Bio-One is part of Greiner Holding, which is based in Kremsmünster (Austria).